BeStock  
Stocks › Biotechnology › ARQT

Arcutis Biotherapeutics ARQT

US equityMarket cap rank #2353Biotechnology
$26.36 −$0.81 (-2.98%)
Market closed · Nov 22, 5:10 am ET · Last extended-hours $26.40 +0.15%
Open$26.91
Prev close$27.17
Day range$26.29 – $27.47
Volume1.29M
Market cap$3.33B
P/E (TTM)119.8
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings128.5x
CheapRich

Near the top of its 5-year range · 99th percentile, 5-year average -70.8x

#2874 of 2993 stocks by PE (1 = cheapest)

Price / book14.7x
CheapRich

Near the top of its 5-year range · 80th percentile, 5-year average 9.1x

#5067 of 5330 stocks by PB (1 = cheapest)

Price / sales7.0x
CheapRich

Below its usual level · 29th percentile, 5-year average 101.1x

#4270 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-1,555x-926x-297x331xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$24.74
Price vs. fair value+6.5%Trading above the estimate
Star rating★★★☆☆
Economic moatNarrow
UncertaintyHigh
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 14.65 – 9.12 80% (pricier than usual) #5067 of 5330 (1 = cheapest)
PE 128.45 46.14 -70.84 99% (pricier than usual) #2874 of 2993 (1 = cheapest)
PS 7.03 5.48 101.09 29% (cheaper than usual) #4270 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on ARQT.

Sign in to join the discussion.

Scroll to Top